Cargando…
Selected strategies to fight pathogenic bacteria
Natural products and analogues are a source of antibacterial drug discovery. Considering drug resistance levels emerging for antibiotics, identification of bacterial metalloenzymes and the synthesis of selective inhibitors are interesting for antibacterial agent development. Peptide nucleic acids ar...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9848314/ https://www.ncbi.nlm.nih.gov/pubmed/36629427 http://dx.doi.org/10.1080/14756366.2022.2155816 |
_version_ | 1784871682690777088 |
---|---|
author | Plotniece, Aiva Sobolev, Arkadij Supuran, Claudiu T. Carta, Fabrizio Björkling, Fredrik Franzyk, Henrik Yli-Kauhaluoma, Jari Augustyns, Koen Cos, Paul De Vooght, Linda Govaerts, Matthias Aizawa, Juliana Tammela, Päivi Žalubovskis, Raivis |
author_facet | Plotniece, Aiva Sobolev, Arkadij Supuran, Claudiu T. Carta, Fabrizio Björkling, Fredrik Franzyk, Henrik Yli-Kauhaluoma, Jari Augustyns, Koen Cos, Paul De Vooght, Linda Govaerts, Matthias Aizawa, Juliana Tammela, Päivi Žalubovskis, Raivis |
author_sort | Plotniece, Aiva |
collection | PubMed |
description | Natural products and analogues are a source of antibacterial drug discovery. Considering drug resistance levels emerging for antibiotics, identification of bacterial metalloenzymes and the synthesis of selective inhibitors are interesting for antibacterial agent development. Peptide nucleic acids are attractive antisense and antigene agents representing a novel strategy to target pathogens due to their unique mechanism of action. Antisense inhibition and development of antisense peptide nucleic acids is a new approach to antibacterial agents. Due to the increased resistance of biofilms to antibiotics, alternative therapeutic options are necessary. To develop antimicrobial strategies, optimised in vitro and in vivo models are needed. In vivo models to study biofilm-related respiratory infections, device-related infections: ventilator-associated pneumonia, tissue-related infections: chronic infection models based on alginate or agar beads, methods to battle biofilm-related infections are discussed. Drug delivery in case of antibacterials often is a serious issue therefore this review includes overview of drug delivery nanosystems. |
format | Online Article Text |
id | pubmed-9848314 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-98483142023-01-19 Selected strategies to fight pathogenic bacteria Plotniece, Aiva Sobolev, Arkadij Supuran, Claudiu T. Carta, Fabrizio Björkling, Fredrik Franzyk, Henrik Yli-Kauhaluoma, Jari Augustyns, Koen Cos, Paul De Vooght, Linda Govaerts, Matthias Aizawa, Juliana Tammela, Päivi Žalubovskis, Raivis J Enzyme Inhib Med Chem Review Article Natural products and analogues are a source of antibacterial drug discovery. Considering drug resistance levels emerging for antibiotics, identification of bacterial metalloenzymes and the synthesis of selective inhibitors are interesting for antibacterial agent development. Peptide nucleic acids are attractive antisense and antigene agents representing a novel strategy to target pathogens due to their unique mechanism of action. Antisense inhibition and development of antisense peptide nucleic acids is a new approach to antibacterial agents. Due to the increased resistance of biofilms to antibiotics, alternative therapeutic options are necessary. To develop antimicrobial strategies, optimised in vitro and in vivo models are needed. In vivo models to study biofilm-related respiratory infections, device-related infections: ventilator-associated pneumonia, tissue-related infections: chronic infection models based on alginate or agar beads, methods to battle biofilm-related infections are discussed. Drug delivery in case of antibacterials often is a serious issue therefore this review includes overview of drug delivery nanosystems. Taylor & Francis 2023-01-11 /pmc/articles/PMC9848314/ /pubmed/36629427 http://dx.doi.org/10.1080/14756366.2022.2155816 Text en © 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Plotniece, Aiva Sobolev, Arkadij Supuran, Claudiu T. Carta, Fabrizio Björkling, Fredrik Franzyk, Henrik Yli-Kauhaluoma, Jari Augustyns, Koen Cos, Paul De Vooght, Linda Govaerts, Matthias Aizawa, Juliana Tammela, Päivi Žalubovskis, Raivis Selected strategies to fight pathogenic bacteria |
title | Selected strategies to fight pathogenic bacteria |
title_full | Selected strategies to fight pathogenic bacteria |
title_fullStr | Selected strategies to fight pathogenic bacteria |
title_full_unstemmed | Selected strategies to fight pathogenic bacteria |
title_short | Selected strategies to fight pathogenic bacteria |
title_sort | selected strategies to fight pathogenic bacteria |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9848314/ https://www.ncbi.nlm.nih.gov/pubmed/36629427 http://dx.doi.org/10.1080/14756366.2022.2155816 |
work_keys_str_mv | AT plotnieceaiva selectedstrategiestofightpathogenicbacteria AT sobolevarkadij selectedstrategiestofightpathogenicbacteria AT supuranclaudiut selectedstrategiestofightpathogenicbacteria AT cartafabrizio selectedstrategiestofightpathogenicbacteria AT bjorklingfredrik selectedstrategiestofightpathogenicbacteria AT franzykhenrik selectedstrategiestofightpathogenicbacteria AT ylikauhaluomajari selectedstrategiestofightpathogenicbacteria AT augustynskoen selectedstrategiestofightpathogenicbacteria AT cospaul selectedstrategiestofightpathogenicbacteria AT devooghtlinda selectedstrategiestofightpathogenicbacteria AT govaertsmatthias selectedstrategiestofightpathogenicbacteria AT aizawajuliana selectedstrategiestofightpathogenicbacteria AT tammelapaivi selectedstrategiestofightpathogenicbacteria AT zalubovskisraivis selectedstrategiestofightpathogenicbacteria |